Rice University researchers in the lab of chemist Han Xiao have identified a promising new immunological pathway to treat stubborn bone tumors, one of most prevalent forms of metastases in breast cancer patients.
Destruction of documents, insufficient data lead FDA to reject hep B vaccine update
Dynavax’s hepatitis B vaccine was rejected for a label expansion in the US after patient data was destroyed by a third-party clinical trial site operator,
May 15, 2024